Eli Lilly and Co
LLY
Eli Lilly and Co News & Analysis
stocks
Eli Lilly earnings: Mounjaro/Zepbound’s massive volume growth more than counters price pressure
We’ve raised our fair value estimate of Lilly stock.
stocks
A wave of US biotech IPOs may be starting - here’s why
M&A activity is bolstering IPOs within key areas of the biotech space. A GLP-1 maker and a protein biomarker detection company are the latest.
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
Wide moat Eli Lilly receives FDA approval for obesity pill.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,875.70 | 21.00 | 0.24% |
| CAC 40 | 7,897.19 | 61.88 | 0.79% |
| DAX 40 | 25,231.20 | 291.85 | 1.17% |
| Dow JONES (US) | 51,176.96 | 250.40 | 0.49% |
| FTSE 100 | 10,461.95 | 33.68 | 0.32% |
| HKSE | 23,972.29 | 640.98 | -2.60% |
| NASDAQ | 27,190.86 | 319.27 | 1.19% |
| Nikkei 225 | 69,901.46 | 1,592.00 | 2.33% |
| NZX 50 Index | 13,663.84 | 16.65 | -0.12% |
| S&P 500 | 7,722.72 | 56.27 | 0.73% |
| S&P/ASX 200 | 8,702.10 | 20.00 | 0.23% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |